Retatrutide

Retatrutide goes a step beyond the dual agonists by activating three receptors: GIP, GLP-1, and glucagon. The first two are the incretin pathways shared with semaglutide and tirzepatide; the third — glucagon — is the novel addition and the reason it draws so much attention.

The incretin arms do the expected work: more glucose-dependent insulin, more fullness, slower stomach emptying. The glucagon arm is thought to add something the others don't — raising energy expenditure and helping the liver clear fat. That extra 'burn' on top of reduced intake is the leading hypothesis for why early trials produced some of the largest weight reductions seen in this class.

It is still investigational, with headline data from phase 2 and phase 3 ongoing. Because glucagon signaling can also raise blood glucose and heart rate, the three-way receptor balance has to be tuned carefully, and long-term safety isn't established. Treat the striking early numbers as promising but unconfirmed.  Edit Text Edit text